Protocol Ledger

NCT04893109 · Phase II · RECRUITING

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Interventional Phase II clinical trial protocol NCT04893109 sponsored by Dana-Farber Cancer Institute in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-06-16 Enrollment: 500 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04893109
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)500 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04893109
Protocol FieldVerified Registry Value
NCT IdentifierNCT04893109
Consolidated Lead SponsorDana-Farber Cancer Institute
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment500 participants (ESTIMATED)
Registered Start Date2021-06-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Dana-Farber Cancer Institute across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI